Your browser doesn't support javascript.
loading
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.
Lovly, Christine M; McDonald, Nerina T; Chen, Heidi; Ortiz-Cuaran, Sandra; Heukamp, Lukas C; Yan, Yingjun; Florin, Alexandra; Ozretic, Luka; Lim, Diana; Wang, Lu; Chen, Zhao; Chen, Xi; Lu, Pengcheng; Paik, Paul K; Shen, Ronglai; Jin, Hailing; Buettner, Reinhard; Ansén, Sascha; Perner, Sven; Brockmann, Michael; Bos, Marc; Wolf, Jürgen; Gardizi, Masyar; Wright, Gavin M; Solomon, Benjamin; Russell, Prudence A; Rogers, Toni-Maree; Suehara, Yoshiyuki; Red-Brewer, Monica; Tieu, Rudy; de Stanchina, Elisa; Wang, Qingguo; Zhao, Zhongming; Johnson, David H; Horn, Leora; Wong, Kwok-Kin; Thomas, Roman K; Ladanyi, Marc; Pao, William.
Afiliação
  • Lovly CM; Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
  • McDonald NT; Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
  • Chen H; Department of Biostatistics, Vanderbilt University, Nashville, Tennessee, USA.
  • Ortiz-Cuaran S; Department of Translational Genomics, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, Cologne, Germany.
  • Heukamp LC; 1] Department of Pathology, Center for Integrated Oncology Köln-Bonn, University Hospital Cologne, Cologne, Germany. [2] New Oncology, Cologne, Germany.
  • Yan Y; Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
  • Florin A; Department of Pathology, Center for Integrated Oncology Köln-Bonn, University Hospital Cologne, Cologne, Germany.
  • Ozretic L; Department of Pathology, Center for Integrated Oncology Köln-Bonn, University Hospital Cologne, Cologne, Germany.
  • Lim D; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Wang L; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Chen Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Chen X; Department of Biostatistics, Vanderbilt University, Nashville, Tennessee, USA.
  • Lu P; Department of Biostatistics, Vanderbilt University, Nashville, Tennessee, USA.
  • Paik PK; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Shen R; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Jin H; Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
  • Buettner R; Department of Pathology, Center for Integrated Oncology Köln-Bonn, University Hospital Cologne, Cologne, Germany.
  • Ansén S; Department of Internal Medicine (Department I), Center for Integrated Oncology Köln-Bonn, University Hospital Cologne, Cologne, Germany.
  • Perner S; Department of Prostate Cancer Research, Institute of Pathology, Center of Integrated Oncology Köln-Bonn, University Hospital of Bonn, Bonn, Germany.
  • Brockmann M; Department of Pathology, Hospital Merheim, Cologne, Germany.
  • Bos M; 1] Department of Translational Genomics, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, Cologne, Germany. [2] Department of Internal Medicine (Department I), Center for Integrated Oncology Köln-Bonn, University Hospital Cologne, Cologne, Germany.
  • Wolf J; Department of Internal Medicine (Department I), Center for Integrated Oncology Köln-Bonn, University Hospital Cologne, Cologne, Germany.
  • Gardizi M; Department of Internal Medicine (Department I), Center for Integrated Oncology Köln-Bonn, University Hospital Cologne, Cologne, Germany.
  • Wright GM; Department of Surgery, University of Melbourne, St. Vincent's Hospital, Melbourne, Victoria, Australia.
  • Solomon B; Division of Hematology and Medical Oncology, Peter MacCallum Cancer Center, Melbourne, Australia.
  • Russell PA; Department of Anatomical Pathology, St. Vincent's Hospital, Melbourne, Victoria, Australia.
  • Rogers TM; Department of Pathology, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.
  • Suehara Y; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Red-Brewer M; Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
  • Tieu R; Anti-tumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • de Stanchina E; Anti-tumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Wang Q; Department of Biomedical Informatics, Vanderbilt University, Nashville, Tennessee, USA.
  • Zhao Z; Department of Biomedical Informatics, Vanderbilt University, Nashville, Tennessee, USA.
  • Johnson DH; Department of Medicine, UT Southwestern School of Medicine, Dallas, Texas, USA.
  • Horn L; Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
  • Wong KK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Thomas RK; 1] Department of Translational Genomics, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, Cologne, Germany. [2] Department of Pathology, Center for Integrated Oncology Köln-Bonn, University Hospital Cologne, Cologne, Germany.
  • Ladanyi M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Pao W; Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
Nat Med ; 20(9): 1027-34, 2014 Sep.
Article em En | MEDLINE | ID: mdl-25173427

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Piridinas / Receptor IGF Tipo 1 / Receptores Proteína Tirosina Quinases / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Female / Humans / Middle aged Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Piridinas / Receptor IGF Tipo 1 / Receptores Proteína Tirosina Quinases / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Female / Humans / Middle aged Idioma: En Ano de publicação: 2014 Tipo de documento: Article